Argenx sets R&D focus with autoimmune myositis webinar, shares in analyst spotlight

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 13:29.

Argenx SE (NL0010832176) underpins its immunology pipeline narrative with a dedicated R&D webinar on autoimmune myositis, while its ADRs trade on Nasdaq under the ticker ARGX. The company flagged the event in an investor communication and a subsequent Form 6-K filing with the U.S. Securities and Exchange Commission.

What the R&D webinar covers

According to an Argenx press announcement distributed via GlobeNewswire, the company will host an autoimmune myositis R&D webinar under the theme "Advancing FcRn Leadership in Autoimmune Myositis" later in June 2026, with management and external experts participating.

The live webcast will be accessible through the investors section of the Argenx website, and a replay together with presentation slides is scheduled to remain available for approximately one year after the event.

How Wall Street views Argenx

Argenx is closely followed on Wall Street, where its ADRs trade on Nasdaq alongside sector peers such as Regeneron and Alexion’s acquirer AstraZeneca. Recent analyst commentary has been supportive of the stock’s long-term autoimmune thesis.

In a recent round of updates, Wells Fargo lifted its Argenx price target to 1,291 U.S. dollars from 1,260 dollars and reiterated an Overweight rating, while Stifel raised its target to 1,255 dollars from 1,222 dollars and maintained a Buy recommendation, as summarized in a market commentary on Argenx and its FcRn franchise.

The product behind the stock

Argenx generates its revenue primarily from its antibody fragment-based therapy Vyvgart (efgartigimod), which targets the neonatal Fc receptor (FcRn) and is approved in several markets for generalized myasthenia gravis, positioning the company as a specialist in FcRn-mediated autoimmune disease treatment.

Where the Argenx shares trade today

The Argenx ADRs (NL0010832176) closed on Nasdaq at 903.75 U.S. dollars on 2026-06-22, 16:00 Eastern Time, according to recent price data.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results. Readers should conduct their own research and, where appropriate, consult a licensed financial advisor.